Skip to main content
. 2022 Jul 8;13:918731. doi: 10.3389/fimmu.2022.918731

Figure 1.

Figure 1

Binding of monomeric C-reactive protein (mCRP) to the spike receptor-binding domain (RBD). Different concentrations of (A) recombinant mCRP (r-mCRP) (n = 3), (B) urea-denatured mCRP (u-mCRP) (n = 3), and (C) pCRP were added to spike RBD-immobilized microtiter wells. Binding was detected with the mCRP-specific mAb 3H12 or the pCRP-specific mAb 8D8. mCRP obtained in different ways showed strong binding to the spike RBD, whereas pCRP did not (n = 3). (D) Surface plasmon resonance (SPR) assays to detect the binding of mCRP to the spike RBD. mCRP was injected in the fluid phase into spike RBD-conjugated to CM5 chips. CM5 chips without spike RBD conjugation were used as controls. Dose-dependent binding was observed with mCRP. (E) SPR assays to detect the binding of angiotensin-converting enzyme 2 (ACE2) to spike RBD. The binding of spike RBD to ACE2 was detected using SPR to determine the biological activity of spike RBD protein used in the binding experiment. All results are presented as means ± S.E.M.